Peptide medicines and experimental peptides differ in their evidence, approved uses, and risks. These three groups should not be treated as interchangeable.
1. Incretin medicines (semaglutide, tirzepatide)
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both GIP and GLP-1 receptors. Products have different approved indications; a clinician must assess whether a particular medicine is appropriate.
In trials of adults with overweight or obesity without diabetes, semaglutide 2.4 mg produced an average 14.9% weight reduction at 68 weeks. Tirzepatide produced average reductions of 15.0% to 20.9% at 72 weeks across the studied doses. Participants also received lifestyle support. These are trial averages, not a prediction for an individual or a direct comparison between the medicines.
What to discuss: Gastrointestinal side effects can occur. The medicine's approved label, health history, other medicines, and treatment response guide prescribing and dose changes; side effects should not simply be assumed to fade.
2. Growth hormone secretagogues (sermorelin, ipamorelin)
Growth hormone secretagogues stimulate growth hormone release rather than supplying growth hormone directly. That mechanism alone does not establish that a product is safer than growth hormone or effective for age-related recovery concerns.
Claims that these products reliably improve sleep, recovery, or body composition in otherwise healthy aging men need product-specific clinical evidence. They should not be presented as established benefits.
Age over 40, slower recovery, or fatigue alone does not establish a treatment indication. FDA has identified potential safety concerns and gaps in safety information for compounded ipamorelin.
3. Recovery and joint peptides (BPC-157, TB-500)
BPC-157 and the thymosin beta-4 fragment commonly called TB-500 are promoted for tissue recovery. Animal findings do not establish clinical benefit in people, and evidence about full-length thymosin beta-4 should not be assumed to apply to a fragment.
FDA identifies potential safety risks and limited human safety information for BPC-157 and the thymosin beta-4 fragment. These should not be presented as established treatments for tendon, ligament, or joint problems.
What peptides aren't
The word peptide does not establish a product's effectiveness, safety, or reversibility. Evidence and risks must be assessed for the specific medicine and intended use.
What to discuss with a clinician
Discuss the health concern, treatment goals, medical history, and medicines you already take. Any testing should address that assessment; there is no single bloodwork panel that establishes a need for every product described here.
Ask what evidence supports the proposed use, which risks are known, and what remains uncertain. A prescription or a compounded preparation does not by itself establish safety or effectiveness.
Sources
FDA: tirzepatide for chronic weight management; FDA: safety concerns with certain compounded substances; STEP 1 semaglutide trial; SURMOUNT-1 tirzepatide trial; FDA evaluation of ipamorelin acetate.